이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
TG Therapeutics 관리
관리 기준 확인 3/4
TG Therapeutics' CEO는 Mike Weiss, Dec2011 에 임명되었습니다 의 임기는 12.5 년입니다. 총 연간 보상은 $ 15.84M, 5.5% 로 구성됩니다. 5.5% 급여 및 94.5% 보너스(회사 주식 및 옵션 포함). 는 $ 137.53M 가치에 해당하는 회사 주식의 5.73% 직접 소유합니다. 137.53M. 경영진과 이사회의 평균 재임 기간은 각각 12.5 년과 10.5 년입니다.
주요 정보
Mike Weiss
최고 경영자
US$15.8m
총 보상
| CEO 급여 비율 | 5.5% |
| CEO 임기 | 12.5yrs |
| CEO 소유권 | 5.7% |
| 경영진 평균 재임 기간 | 12.5yrs |
| 이사회 평균 재임 기간 | 10.5yrs |
최근 관리 업데이트
Recent updates
Hold TG Therapeutics For Intriguing Outcomes
Jun 12TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement
May 29
TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 04TG Therapeutics: Less Room For Doubt About Briumvi
May 03News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
May 03TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet
Mar 25TG Therapeutics: Briumvi Growth Story Appears Intact
Mar 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Mar 01TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference
Jan 10Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S
Jan 04Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Nov 24TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar
Sep 30Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
Aug 03Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jul 19Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
Apr 13Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?
Jan 02TG Therapeutics: Elucidating The Upcoming Binary
Oct 09TG Therapeutics: We Are Just Hanging In There
Sep 21Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt
Sep 07TG Therapeutics announces peer-reviewed publication of multiple sclerosis phase 3 trials
Aug 25TG Therapeutics Q2 2022 Earnings Preview
Aug 05TG Therapeutics And Ublituximab: From Icing To Lifeline
Jul 08Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jun 06TG Therapeutics: I May Double Down Again
Apr 18CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$41m |
| Dec 31 2023 | US$16m | US$875k | US$13m |
| Sep 30 2023 | n/a | n/a | -US$26m |
| Jun 30 2023 | n/a | n/a | -US$176m |
| Mar 31 2023 | n/a | n/a | -US$169m |
| Dec 31 2022 | US$10m | US$875k | -US$198m |
| Sep 30 2022 | n/a | n/a | -US$239m |
| Jun 30 2022 | n/a | n/a | -US$288m |
| Mar 31 2022 | n/a | n/a | -US$326m |
| Dec 31 2021 | US$43m | US$1m | -US$348m |
| Sep 30 2021 | n/a | n/a | -US$343m |
| Jun 30 2021 | n/a | n/a | -US$345m |
| Mar 31 2021 | n/a | n/a | -US$319m |
| Dec 31 2020 | US$32m | US$1m | -US$279m |
| Sep 30 2020 | n/a | n/a | -US$231m |
| Jun 30 2020 | n/a | n/a | -US$206m |
| Mar 31 2020 | n/a | n/a | -US$189m |
| Dec 31 2019 | US$13m | US$637k | -US$173m |
| Sep 30 2019 | n/a | n/a | -US$187m |
| Jun 30 2019 | n/a | n/a | -US$159m |
| Mar 31 2019 | n/a | n/a | -US$167m |
| Dec 31 2018 | US$14m | US$656k | -US$173m |
| Sep 30 2018 | n/a | n/a | -US$150m |
| Jun 30 2018 | n/a | n/a | -US$148m |
| Mar 31 2018 | n/a | n/a | -US$132m |
| Dec 31 2017 | US$10m | US$525k | -US$118m |
보상 대 시장: Mike 의 총 보상 ($USD 15.84M )은 US 시장( $USD 6.80M ).
보상과 수익: Mike 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Mike Weiss (58 yo)
12.5yrs
테뉴어
US$15,837,559
보상
Mr. Michael S. Weiss, Esq. J.D. also known as Mike, serves as Director of Urica Therapeutics, Inc. He has been an Executive Chairman of Mustang Bio, Inc. since January 2017 and served as its Interim Presid...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman | 12.5yrs | US$15.84m | 5.73% $ 139.3m | |
| CFO, Corporate Secretary & Treasurer | 12.5yrs | US$1.87m | 0.48% $ 11.6m | |
| Senior Vice President of Corporate Communications | no data | 데이터 없음 | 데이터 없음 | |
| Chief Commercialization Officer | 6yrs | 데이터 없음 | 데이터 없음 |
12.5yrs
평균 재임 기간
경험이 풍부한 관리: TGTX 의 관리팀은 노련하고 경험 (평균 재직 기간 12.5 년)입니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman | 12.5yrs | US$15.84m | 5.73% $ 139.3m | |
| Lead Independent Director | 12.2yrs | US$304.70k | 0.15% $ 3.7m | |
| Independent Director | 9.5yrs | US$264.70k | 0.17% $ 4.1m | |
| Independent Director | 11.6yrs | US$262.20k | 0.15% $ 3.8m | |
| Independent Director | 4.2yrs | US$259.70k | 0.076% $ 1.8m | |
| Independent Director | 9yrs | US$262.20k | 0.15% $ 3.7m |
10.5yrs
평균 재임 기간
58.5yo
평균 연령
경험이 풍부한 이사회: TGTX 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 10.5 년).